These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 12056713)

  • 1. Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours.
    Bajetta E; Ferrari L; Procopio G; Catena L; Ferrario E; Martinetti A; Di Bartolomeo M; Buzzoni R; Celio L; Vitali M; Beretta E; Seregni E; Bombardieri E
    Ann Oncol; 2002 Apr; 13(4):614-21. PubMed ID: 12056713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the combination 5-fluorouracil, dacarbazine, and epirubicin in patients with advanced well-differentiated neuroendocrine tumors.
    Walter T; Bruneton D; Cassier PA; Hervieu V; Pilleul F; Scoazec JY; Chayvialle JA; Lombard-Bohas C
    Clin Colorectal Cancer; 2010 Oct; 9(4):248-54. PubMed ID: 20920998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 5-Fluorouracil, dacarbazine, and epirubicin in the treatment of patients with neuroendocrine tumors.
    Bajetta E; Rimassa L; Carnaghi C; Seregni E; Ferrari L; Di Bartolomeo M; Regalia E; Cassata A; Procopio G; Mariani L
    Cancer; 1998 Jul; 83(2):372-8. PubMed ID: 9669822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: an ITMO group study.
    Bajetta E; Catena L; Fazio N; Pusceddu S; Biondani P; Blanco G; Ricci S; Aieta M; Pucci F; Valente M; Bianco N; Mauri CM; Spada F
    Cancer; 2014 Aug; 120(16):2457-63. PubMed ID: 24752410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II trial of dacarbazine, fluorouracil and epirubicin in patients with neuroendocrine tumours. A study by the Italian Trials in Medical Oncology (I.T.M.O.) Group.
    Di Bartolomeo M; Bajetta E; Bochicchio AM; Carnaghi C; Somma L; Mazzaferro V; Visini M; Gebbia V; Tumolo S; Ballatore P
    Ann Oncol; 1995 Jan; 6(1):77-9. PubMed ID: 7710986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of advanced neuroendocrine tumours using combination chemotherapy with lomustine and 5-fluorouracil.
    Kaltsas GA; Mukherjee JJ; Isidori A; Kola B; Plowman PN; Monson JP; Grossman AB; Besser GM
    Clin Endocrinol (Oxf); 2002 Aug; 57(2):169-83. PubMed ID: 12153595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selecting patients for cytotoxic therapies in gastroenteropancreatic neuroendocrine tumours.
    Costa FP; Gumz B; Pasche B
    Best Pract Res Clin Gastroenterol; 2012 Dec; 26(6):843-54. PubMed ID: 23582923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of neuroendocrine tumours with infusional 5-fluorouracil, folinic acid and streptozocin.
    Gonzalez MA; Biswas S; Clifton L; Corrie PG
    Br J Cancer; 2003 Aug; 89(3):455-6. PubMed ID: 12888810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy.
    Saif MW; Kaley K; Brennan M; Garcon MC; Rodriguez G; Rodriguez T
    JOP; 2013 Sep; 14(5):498-501. PubMed ID: 24018594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy and safety of everolimus for the treatment of progressive gastroenteropancreatic neuroendocrine tumors: A multi-institution observational study in Taiwan.
    Liu CT; Chen MH; Chen JS; Chen LT; Shan YS; Lu CH; Su YL; Ku FC; Chou WC; Chen YY
    Asia Pac J Clin Oncol; 2016 Dec; 12(4):396-402. PubMed ID: 27357443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of epirubicin plus oxaliplatin and infusional 5-fluorouracil as first-line combination therapy in patients with metastatic or advanced gastric cancer.
    Zhang CX; Huang S; Xu N; Fang JW; Shen P; Bao YH; Mou BH; Shi MG; Zhong XL; Xiong PJ
    Anticancer Drugs; 2007 Jun; 18(5):581-6. PubMed ID: 17414627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Endostar combined with chemotherapy in advanced well-differentiated pancreatic neuroendocrine tumors.
    Cheng YJ; Meng CT; Ying HY; Zhou JF; Yan XY; Gao X; Zhou N; Bai CM
    Medicine (Baltimore); 2018 Nov; 97(45):e12750. PubMed ID: 30407280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Streptozocin/5-fluorouracil chemotherapy is associated with durable response in patients with advanced pancreatic neuroendocrine tumours.
    Dilz LM; Denecke T; Steffen IG; Prasad V; von Weikersthal LF; Pape UF; Wiedenmann B; Pavel M
    Eur J Cancer; 2015 Jul; 51(10):1253-62. PubMed ID: 25935542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating bevacizumab in combination with FOLFIRI after the failure of platinum-etoposide regimen in patients with advanced poorly differentiated neuroendocrine carcinoma: The PRODIGE 41-BEVANEC randomized phase II study.
    Walter T; Malka D; Hentic O; Lombard-Bohas C; Le Malicot K; Smith D; Ferru A; Assenat E; Cadiot G; Lievre A; Kurtz JE; Dahan L; Dubreuil O; Hautefeuille V; Lepere C; Gangloff A; Elhajbi F; Coriat R; Roquin G; Bouarioua N; Granger V; Scoazec JY; Lepage C
    Dig Liver Dis; 2018 Feb; 50(2):195-198. PubMed ID: 29258812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II clinical trial of parenteral hydroxyurea in combination with fluorouracil, interferon and filgrastim in the treatment of advanced pancreatic, gastric and neuroendocrine tumors.
    Kaubisch A; Kaleya R; Haynes H; Rozenblit A; Wadler S
    Cancer Chemother Pharmacol; 2004 Apr; 53(4):337-40. PubMed ID: 14704829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized prospective phase II study to compare the combination chemotherapy regimen epirubicin, cisplatin, and 5-fluorouracil with epirubicin, cisplatin, and capecitabine in patients with advanced or metastatic gastric cancer.
    Ocvirk J; Reberšek M; Skof E; Hlebanja Z; Boc M
    Am J Clin Oncol; 2012 Jun; 35(3):237-41. PubMed ID: 21399488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy for neuroendocrine tumors: the Beatson Oncology Centre experience.
    Hatton MQ; Reed NS
    Clin Oncol (R Coll Radiol); 1997; 9(6):385-9. PubMed ID: 9448967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of FOLFOX Chemotherapy in Metastatic Enteropancreatic Neuroendocrine Tumors.
    Oziel-Taieb S; Zemmour C; Raoul JL; Mineur L; Poizat F; Charrier N; Piana G; Cavaglione G; Niccoli P
    Anticancer Res; 2021 Apr; 41(4):2071-2078. PubMed ID: 33813416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience.
    Fine RL; Gulati AP; Krantz BA; Moss RA; Schreibman S; Tsushima DA; Mowatt KB; Dinnen RD; Mao Y; Stevens PD; Schrope B; Allendorf J; Lee JA; Sherman WH; Chabot JA
    Cancer Chemother Pharmacol; 2013 Mar; 71(3):663-70. PubMed ID: 23370660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of first-line systemic chemotherapy with epirubicin, cisplatin plus 5-fluorouracil and docetaxel, cisplatin plus 5-fluorouracil regimens in locally advanced inoperable or metastatic gastric or gastroesophageal junction adenocarcinoma: A prospective phase II study from South India.
    Babu KG; Chaudhuri T; Lakshmaiah KC; Dasappa L; Jacob LA; Babu M; Rudresha AH; Lokesh KN; Rajeev LK
    Indian J Cancer; 2017; 54(1):47-51. PubMed ID: 29199662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.